Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM. These infections can present in a variety of patients, including those with cystic fibrosis, although Insmed is excluding these patients from its trials. Insmed has also conducted trials of Arikayce for the specific treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients. However, this indication has been deprioritized in favor of further developing the drug for the NTM market opportunity.
LIST OF FIGURES
8 Figure 1: Arikayce for cystic fibrosis – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Arikayce for cystic fibrosis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Arikayce for cystic fibrosis
LIST OF TABLES
6 Table 1: Arikayce drug profile
7 Table 2: Arikayce Phase III data in cystic fibrosis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.